Ardelyx (NASDAQ: ARDX) recently received a number of ratings updates from brokerages and research firms:

  • 11/29/2017 – Ardelyx had its price target raised by analysts at Citigroup Inc. from $16.00 to $17.00. They now have a “buy” rating on the stock.
  • 11/28/2017 – Ardelyx had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, down previously from $13.00.
  • 11/28/2017 – Ardelyx was given a new $12.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/22/2017 – Ardelyx had its price target lowered by analysts at Ladenburg Thalmann Financial Services from $19.00 to $16.00. They now have a “buy” rating on the stock.
  • 11/21/2017 – Ardelyx had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $12.00 price target on the stock.
  • 11/10/2017 – Ardelyx was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “buy” rating. They now have a $6.50 price target on the stock. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company’s lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. “
  • 10/17/2017 – Ardelyx was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company’s lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. “
  • 10/17/2017 – Ardelyx had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $13.00 price target on the stock.
  • 10/12/2017 – Ardelyx had its price target raised by analysts at Citigroup Inc. from $14.00 to $19.00. They now have a “buy” rating on the stock.
  • 10/12/2017 – Ardelyx had its price target raised by analysts at Cantor Fitzgerald from $12.00 to $14.00. They now have an “overweight” rating on the stock.
  • 10/11/2017 – Ardelyx was given a new $12.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.

Ardelyx, Inc. (NASDAQ ARDX) opened at $5.85 on Thursday. Ardelyx, Inc. has a 52-week low of $4.05 and a 52-week high of $16.30.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.10. During the same period last year, the firm earned ($0.65) EPS. research analysts predict that Ardelyx, Inc. will post -2.01 EPS for the current year.

In other news, COO Reginald Seeto sold 10,008 shares of the company’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $5.20, for a total transaction of $52,041.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 15.47% of the stock is owned by corporate insiders.

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Receive News & Ratings for Ardelyx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc and related companies with MarketBeat.com's FREE daily email newsletter.